BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Alane Barnes Sells 19,770 Shares of Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) insider Alane Barnes sold 19,770 shares of the stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $7.65, for a total value of $151,240.50. Following the completion of the sale, the insider owned 345,476 shares in the company, valued at approximately $2,642,891.40. This trade represents a 5.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

BioCryst Pharmaceuticals Price Performance

BCRX stock opened at $7.85 on Thursday. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.31. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -157.00 and a beta of 0.91. The company has a fifty day moving average price of $7.12 and a two-hundred day moving average price of $8.37.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The company had revenue of $159.40 million for the quarter, compared to analyst estimates of $162.91 million. BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The business’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.07) EPS. Research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in BCRX. Vanguard Group Inc. increased its stake in BioCryst Pharmaceuticals by 6.1% in the third quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company’s stock valued at $165,393,000 after acquiring an additional 1,246,633 shares during the last quarter. Deerfield Management Company L.P. boosted its holdings in shares of BioCryst Pharmaceuticals by 159.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after purchasing an additional 7,477,000 shares in the last quarter. State Street Corp increased its stake in shares of BioCryst Pharmaceuticals by 8.9% in the 2nd quarter. State Street Corp now owns 8,505,392 shares of the biotechnology company’s stock valued at $76,208,000 after purchasing an additional 691,988 shares during the last quarter. Alkeon Capital Management LLC raised its holdings in shares of BioCryst Pharmaceuticals by 1.7% during the 1st quarter. Alkeon Capital Management LLC now owns 7,214,021 shares of the biotechnology company’s stock worth $54,105,000 after buying an additional 120,199 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of BioCryst Pharmaceuticals by 22.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 5,225,986 shares of the biotechnology company’s stock worth $39,665,000 after buying an additional 947,431 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BCRX has been the subject of a number of research analyst reports. Needham & Company LLC reduced their price objective on BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, November 4th. Cantor Fitzgerald boosted their target price on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, October 15th. TD Cowen assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 15th. They set a “buy” rating and a $30.00 price target on the stock. Barclays dropped their price objective on shares of BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 4th. Finally, JMP Securities increased their target price on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a research report on Wednesday, October 15th. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.